Ceribell (CBLL) Net Income towards Common Stockholders (2023 - 2026)
Ceribell's (CBLL) quarterly Net Income towards Common Stockholders came in at -$19.7 million in Q1 2026, down 54.47% YoY from -$43.4 million in Q1 2025, and down 45.91% on a QoQ basis from -$13.5 million in Q4 2025.
Ceribell (CBLL) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Ceribell (CBLL) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$19.7 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 54.47% year-over-year to -$19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.4 million (down 35.03% YoY) and the FY2025 annual result came in at -$54.0 million, down 69.15% from the prior year.
- Net Income towards Common Stockholders fell to -$19.7 million in Q1 2026, from -$13.5 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$7.1 million in Q3 2023 to a low of -$19.7 million in Q1 2026.
- A 4-year average of -$11.7 million and a median of -$12.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders slipped 7.56% — and 2026, when it tumbled 54.47%.
- Tracing CBLL's Net Income towards Common Stockholders over 4 years: stood at -$8.3 million in 2023, then sank by 51.99% to -$12.6 million in 2024, then decreased by 7.56% to -$13.5 million in 2025, then slumped by 45.91% to -$19.7 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$19.7 million (Q1 2026), -$13.5 million (Q4 2025), and -$13.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Ceribell | 916.57 Mn | 787.31 Mn | 25.94 Mn | -19.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.27 Mn |
| Mar 31, 2026 | -19.74 Mn |
| Dec 31, 2025 | -13.53 Mn |
| Sep 30, 2025 | -13.47 Mn |
| Jun 30, 2025 | -13.64 Mn |
| Mar 31, 2025 | -12.78 Mn |
| Dec 31, 2024 | -12.58 Mn |
| Sep 30, 2024 | -10.42 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -8.52 Mn |
| Dec 31, 2023 | -8.27 Mn |
| Sep 30, 2023 | -7.05 Mn |